32
Participants
Start Date
August 31, 2007
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
SNS-314
"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
Duke University, Durham
University of Alabama, Birmingham, Birmingham
University of New Mexico, Albuquerque
Stanford University Medical Center, Stanford
Lead Sponsor
Sunesis Pharmaceuticals
INDUSTRY